About Us
Breaking structural limitations.
Expanding treatment possibilities.
Building trusted solutions.
Dear Partners and Stakeholders,
I am Sangwon Jung, CEO of MVRIX.
MVRIX began with a single question:
"Why do biopharmaceuticals still carry so many limitations?"
What we confronted was the structural constraints of therapeutics. The inefficiencies created by complex manufacturing processes. The limited technological options that remained unchanged for decades. And the narrowing patient accessibility that resulted from these barriers. MVRIX set out to develop therapeutics that fundamentally address these limitations.
MVRIX found its answer in protein engineering. We are simplifying complex cell therapies through our Navibody platform and introducing new options to the botulinum toxin market, long dominated by Type A1, through recombinant technology. We have developed these two technologies not as one-time achievements, but as scalable platforms.
The results speak for themselves. We have been selected for three consecutive government R&D projects, secured over 80 global patents, and achieved technology transfer milestones. But these are not merely a list of accomplishments. They represent our journey of connecting scientific discovery to business value, and ultimately to solutions for patients.
MVRIX now stands at a new starting line. Our vision for the future is clear: to lower the barriers to therapeutic development, provide more diverse options, and create solutions trusted by the market. Through sustainable growth, MVRIX will establish itself as a company that expands the possibilities of treatment on the global stage.
Every challenge at MVRIX begins with careful choices and responsible execution. We are grateful to our shareholders and partners who join us on this journey.
Thank you.
